Tapentadol Dosage Forms with Opioid Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical dosage forms for tapentadol do not effectively address the issue of enhanced analgesic properties while minimizing side effects, and there is a lack of formulations that combine tapentadol with an opioid antagonist to improve efficacy and reduce side effects, particularly for prolonged pain relief durations.
Innovation Solution
Development of slow-release dosage forms of tapentadol combined with opioid antagonists like naltrexone or naloxone, along with a second analgesic, to optimize tapentadol's efficacy and reduce side effects, providing effective pain relief for at least 12 to 24 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tapentadol is administered at higher doses to enhance analgesic potency, then pain relief efficacy is improved, but side effects such as nausea and dizziness increase
Solution Approach 1:
The patent applies preliminary anti-action by incorporating an opioid antagonist (such as naltrexone or naloxone) into the dosage form alongside tapentadol. The antagonist is released in a controlled manner to counteract the side effects of tapentadol before they fully manifest, thereby preventing nausea and dizziness while preserving the analgesic efficacy of the full tapentadol dose.
Solution Approach 2:
The opioid antagonist serves as an intermediary substance that mediates between the therapeutic effect and side effects of tapentadol. By introducing this intermediate agent, the patent enables the co-administration of full therapeutic doses of tapentadol while the antagonist selectively blocks the pathways leading to adverse effects, thus resolving the contradiction between potency and tolerability.
2Speed
If immediate release dosage forms are used to provide rapid pain relief, then onset of action is improved, but duration of action is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the dosage form into multiple functional components with different release characteristics. The formulation includes both immediate-release tapentadol for rapid onset and controlled-release tapentadol for prolonged duration, allowing the drug to be segmented into different release phases that simultaneously address both speed and duration requirements.
Solution Approach 2:
The patent implements periodic action through a multi-phase release mechanism where tapentadol is delivered in periodic bursts - an initial rapid release phase followed by sustained release phases. This periodic delivery pattern ensures both quick onset of analgesia and prolonged duration of action, with the antagonist also released periodically to counteract side effects at each phase.
3Duration of action of moving object
If controlled release formulations are used to extend duration of action, then pain relief duration is improved, but onset of action is delayed
Solution Approach 1:
The patent resolves this contradiction through segmentation of the release profile into distinct phases: an initial immediate-release phase that provides rapid onset of action, followed by controlled-release phases that extend the duration of action. This segmented approach allows the formulation to deliver tapentadol quickly at first, then maintain therapeutic levels over an extended period.
4Reliability
If tapentadol is administered alone to maximize analgesic effect, then efficacy is improved, but abuse potential increases
Solution Approach 1:
The patent applies preliminary anti-action by incorporating an opioid antagonist into the dosage form to preemptively counteract abuse potential. When the formulation is misused or taken in excessive amounts, the antagonist blocks the opioid receptors, preventing the euphoric effects and reinforcing punishment associated with abuse, while the analgesic efficacy at therapeutic doses remains intact due to the dual mode of action of tapentadol.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy and or reduce the side effects of tapentadol. The present invention further provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy and or reduce the side effects of tapentadol.